Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148



Status:Terminated
Conditions:Hospital, Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 75
Updated:11/22/2017
Start Date:April 2015
End Date:March 2016

Use our guide to learn which trials are right for you!

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)

Septic shock is a potentially life-threatening condition that can result in multi-organ
dysfunction syndrome (MODS) and mortality. LB1148 was formulated to preserve gut integrity
during physiological shock and ameliorate the subsequent autodigestion leading to MODS and
mortality. The purpose of this study in septic shock patients is to determine if enteral
administration of LB1148 will increase the number of days alive without cardiovascular,
pulmonary or renal replacement therapy through Day 28.

Primary Objective(s):

The primary objective of this study is to determine if enteral administration of LB1148 will
increase the number of days alive without cardiovascular, renal or pulmonary organ support
through Day 28.

The secondary objectives of this study are to determine if LB1148 will:

- Reduce mortality at Day 7, Day 28 and Day 90;

- Reduce the number of days to organ dysfunction resolution as evidenced by Sequential
Organ Failure Assessment (SOFA) score ≤2 in patients alive on Day 28;

- Reduce the daily organ dysfunction as evidenced by average SOFA score through Day 14 and
Day 28;

- Reduce the number of patients with new-onset organ dysfunction at Day 8;

- Increase the number of days alive and free from renal replacement therapy through Day
28;

- Increase the number of days alive and free from renal dysfunction through Day 28;

- Increase the number of days alive and ventilator free through Day 28;

- Increase the number of days alive and free of vasopressors through Day 14 and Day 28;

- Increase the numbers of days alive and free from liver dysfunction through Day 28;

- Increase the number of days alive and not in the Intensive Care Unit (ICU) through Day
28;

- Increase the number of days alive and not in the hospital through Day 28, and

- Improve patient functional outcomes through Day 28 as evidenced by the EuroQoL EQ 5D
questionnaire.

In addition, the study will assess the safety and tolerability of LB1148 in patients with
septic shock.

The exploratory objectives of this study are to determine if LB1148 will:

- Reduce the number of patients with new-onset organ dysfunction from Day 9 through Day
16;

- Decrease the number of days to normalize serum lactate (≤2.2 mmol/L) through Day 28;

- Reduce the average daily serum lactate levels through Day 8;

- Increase the number of days alive and free from ileus through Day 8 and Day 28.

Inclusion Criteria:

1. First episode (during the current hospitalization) of documented or suspected sepsis
of peritoneum/abdomen, soft tissue, blood, or non-hospital acquired lung origin.

2. Must be receiving antimicrobial therapy for documented or suspected infection.

3. Must have septic shock requiring vasopressors despite adequate fluid resuscitation of
30 mL/kg crystalloid or colloid equivalent, for either an SBP ≤90 mmHg or a MAP ≤65
mmHg (i.e. must have been unable to maintain adequate blood pressure despite adequate
fluid resuscitation without the use of vasopressors). Note: 30 mL/kg crystalloid is
equivalent to 15 mL/kg colloids.

4. Must have a requirement for vasopressor support after adequate fluid resuscitation,
and, at randomization, must require a minimum dose of at least 1 of the following
vasopressors:

- Norepinephrine ≥5 µg/min;

- Dopamine ≥10 µg/kg/min;

- Phenylephrine ≥25 µg/min;

- Epinephrine ≥5 µg/min, or

- Vasopressin ≥0.03 units/min.

Exclusion Criteria

Patients will not be eligible for participation in the study if they meet ANY of the
following criteria:

1. Age <18 or age ≥76 years.

2. Time elapsed since onset of shock is >24 hours. Onset of shock is defined as the first
administration of a vasopressor given by continuous infusion (i.e. not a single bolus
of norepinephrine, phenylephrine, or ephedrine).

3. Septic shock episode is the second or greater episode in current hospitalization.

Note: patients transferred from another healthcare facility that are still within the
first 24 hours of the first episode of shock are eligible.

4. Have hospital acquired pneumonia.

5. Have genitourinary infections as the cause of septic shock.

6. Unable to maintain a minimum MAP of 60 mmHg despite the presence of vasopressors and
IV fluids.

Note: brief transient BPs below 60 mmHg are not disqualifying.

7. Have a serum lactate measurement <2.5 mmol/L after adequate fluid resuscitation (refer
to Inclusion Criteria #3).

8. Not expected to survive for at least 28 days due to a preexisting, non-shock related
medical condition.

9. Highest total SOFA score (known to staff at the time of randomization) during the
screening period <6.

Note: each individual organ component sub-score is calculated from the highest (worst)
score obtained for that organ during the screening period, up until randomization.

10. Highest total SOFA score (known to staff at the time of randomization) during the
screening period >18.

Note: each individual organ component sub-score is calculated from the highest (worst)
score obtained for that organ during the screening period.

11. Lack of commitment to aggressive source control of infection.

12. The patient or patient's surrogate fails to voluntarily sign an informed consent form
(ICF).

13. Ineligible for feeding tube placement.

14. Chronic renal insufficiency requiring hemodialysis not associated with the current
episode of sepsis.

15. Chronic pulmonary dysfunction requiring mechanical ventilation unrelated to the
current episode of sepsis.

16. Undergoing active radiation or cytotoxic chemotherapy treatment for uncontrolled
malignancy.

Note: hormonal and surgical therapies are permitted.

17. Presence of third degree burns involving >20% body surface area in the 7 days prior to
study entry.

18. Known inability to take the study medication (i.e. complete small bowel obstruction).

19. Has acute meningitis.

20. Have any of the following medical conditions:

- HIV-positive patients whose most recent CD4 count was ≤50/mm3;

- Neutrophils <1000/mm3 unless due to sepsis;

- Received chest compressions as part of CPR during this hospitalization without
neurologic recovery;

- Poorly controlled neoplasm;

- End-stage lung disease or Cystic Fibrosis;

- End-stage liver disease (Child-Pugh Class C [score >10], evidence of portal
hypertension or esophageal varices);

- Severe congestive heart failure (New York Heart Association [NYHA] Class IV or
pre-sepsis ejection fraction <30%);

- Undergone organ transplant (including bone marrow, heart, lung, liver, pancreas,
or small bowel transplantation), or

- Primary ICU admitting diagnosis of acute myocardial infarction (MI).

21. Have relative contraindications to taking TXA or have a believed adverse risk/benefit
ratio for taking the drug. These include patients with:

- Known sensitivity to TXA;

- Recent craniotomy (past 28 days);

- Active cerebrovascular bleed;

- Active thromboembolic disease, (such as deep vein thrombosis, pulmonary embolism
[PE], cerebral thrombosis, ischemic stroke, or acute coronary syndrome [ACS]);

- Acute promyelocytic leukemia taking all-trans retinoic acid for remission
induction or;

- Continuing use of a combined hormonal contraceptive (including combined hormonal
pill, patch or vaginal ring).

22. Exclusion for any other condition that, in the opinion of the investigator or
coordinating center, would preclude the subject from being an appropriate candidate
for the study.

23. Received any other investigational therapy or device within 4 weeks prior to
Screening.

24. Female patients of childbearing potential with a positive urine or serum pregnancy
test or who are not taking (or not willing to take) acceptable birth control measures
(abstinence, intrauterine devices, contraceptive implants or barrier methods) through
Day 28. Additionally, those women who are lactating and insist on breast feeding
within 5 days of the last dose of study drug if their sepsis resolves.

Note: post-partum patients who have a persistent positive pregnancy test (human chorionic
gonadotropin [HCG] values which have not had time to decrease) will be allowed in the
study.
We found this trial at
27
sites
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Sacramento, California 95814
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
506 6th St
Brooklyn, New York 11215
(718) 780-3000
New York Methodist Hospital A voluntary, acute-care teaching hospital, New York Methodist Hospital's mission is...
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Burlington, Massachusetts 01805
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Calgary, Alberta
?
mi
from
Calgary,
Click here to add this to my saved trials
1 Cooper Plaza
Camden, New Jersey 08103
(856) 342-2000
Cooper University Hospital Cooper University Health Care, the clinical campus of Cooper Medical School of...
?
mi
from
Camden, NJ
Click here to add this to my saved trials
CHapel Hill, North Carolina 27599
?
mi
from
CHapel Hill, NC
Click here to add this to my saved trials
1215 Lee St
Charlottesville, Virginia 22903
(434) 924-0211
University of Virginia Health System UVA Health System includes a 604-bed hospital, level I trauma...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Hazard, Kentucky
?
mi
from
Hazard, KY
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Long Beach, California 90801
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Missoula, Montana 59802
?
mi
from
Missoula, MT
Click here to add this to my saved trials
Mobile, Alabama 36685
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Peoria, Illinois 61637
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
759 Chestnut Street
Springfield, Massachusetts 01199
(413) 794 - 0000
Baystate Medical Center Baystate Medical Center (BMC), in Springfield, Massachusetts, is an academic, research, and...
?
mi
from
Springfield, MA
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials